Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
KSE - Delayed Quote KRW

Hanall Biopharma Co., Ltd. (009420.KS)

Compare
25,300.00
-2,050.00
(-7.50%)
At close: 3:30:25 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
138,943,698.75
138,943,698.75
134,909,837.62
109,995,418.98
101,594,443.69
Cost of Revenue
65,637,316.77
65,637,316.77
59,737,569.37
48,024,128.71
41,261,830.70
Gross Profit
73,306,381.98
73,306,381.98
75,172,268.25
61,971,290.27
60,332,612.99
Operating Expense
73,075,907
73,075,907
72,960,908
60,465,503
50,233,494
Operating Income
230,474.98
230,474.98
2,211,360.25
1,505,787.27
10,099,118.99
Net Non Operating Interest Income Expense
419,349.18
419,349.18
1,163,505.04
1,405,006.53
694,363.28
Pretax Income
-183,196.94
-183,196.94
3,202,532.13
1,929,429.57
8,702,090.32
Tax Provision
1,621,646.53
1,621,646.53
-306,075.42
1,677,955.93
-194,046.85
Net Income Common Stockholders
-1,804,843.47
-1,804,843.47
3,508,607.55
251,473.64
8,896,137.17
Basic EPS
-36.00
--
69.00
5.00
174.00
Diluted EPS
-36.00
--
69.00
5.00
174.00
Basic Average Shares
50,134.54
--
50,849.39
50,294.73
51,127.23
Diluted Average Shares
50,134.54
--
50,849.39
50,294.73
51,127.23
Total Operating Income as Reported
230,474.89
230,474.89
2,211,359.60
1,505,787.59
10,099,118.83
Rent Expense Supplemental
1,262,603
1,262,603
1,399,215
1,260,528
1,289,273
Total Expenses
138,713,223.77
138,713,223.77
132,698,477.37
108,489,631.71
91,495,324.70
Net Income from Continuing & Discontinued Operation
-1,804,843.47
-1,804,843.47
3,508,607.55
251,473.64
8,896,137.17
Normalized Income
-1,546,946.59
-1,546,946.59
3,198,547.31
512,229.32
10,039,384.67
Interest Income
490,317
490,317
1,227,368
1,426,881
719,844
Interest Expense
70,967
70,967
63,863
21,875
25,480
Net Interest Income
419,349.18
419,349.18
1,163,505.04
1,405,006.53
694,363.28
EBIT
-112,229.94
-112,229.94
3,266,395.13
1,951,304.57
8,727,570.32
EBITDA
3,008,287.06
3,008,287.06
6,513,340.13
5,003,957.57
11,452,427.32
Reconciled Cost of Revenue
65,637,316.77
65,637,316.77
59,737,569.37
48,024,128.71
41,261,830.70
Reconciled Depreciation
3,120,517
3,120,517
3,246,945
3,052,653
2,724,857
Net Income from Continuing Operation Net Minority Interest
-1,804,843.47
-1,804,843.47
3,508,607.55
251,473.64
8,896,137.17
Total Unusual Items Excluding Goodwill
-339,338
-339,338
407,974
-359,663
-1,524,330
Total Unusual Items
-339,338
-339,338
407,974
-359,663
-1,524,330
Normalized EBITDA
3,347,625.06
3,347,625.06
6,105,366.13
5,363,620.57
12,976,757.32
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-81,441.12
-81,441.12
97,913.76
-98,907.33
-381,082.50
12/31/2021 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GODAVARI.BO Godavari Drugs Limited
92.20
-3.70%
 
237690.KQ ST Pharm Co.,Ltd.
67,300.00
-8.93%
 
000100.KS Yuhan Corporation
103,200.00
-5.93%
 
2561.HK VISEN Pharmaceuticals
40.800
-18.81%
 
MOB.ST Moberg Pharma AB (publ)
6.90
-4.83%
 
ZYDUSLIFE.NS Zydus Lifesciences Limited
837.05
-3.44%
 
EOLS Evolus, Inc.
10.69
-6.15%
 
SBFM Sunshine Biopharma, Inc.
1.5700
-14.67%